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The present study evaluated the effects of morphine or morphine together with corticotrophin
releasing hormone (CRH) on Met-enkephalin synthesis, secretion, concentration and opioid
receptors binding in the hypothalamus, anterior pituitary and adrenal cortex (HPA) in lambs.
Lambs received a single i.v. injection of 0.9% NaCl (control) or morphine (MOR) or
morphine in combination with CRH (MOR+CRH). Animals were decapitated after 60 min
under anaesthesia and fragments of HPA tissues were dissected. Proenkephalin mRNA
expression was measured by in situ hybridization, Met-enkephalin concentrations by RIA
method, opioid secretion by in vitro incubation. Specific radioligands were used for each type
of receptors - 3H-DAGO for mu, 3H-DPDPE for delta and 3H-EKC for kappa binding sites.
Acute injection of morphine affected the proenkephalin mRNA expression, native and
cryptic Met-enkephalin concentrations as well as mu, delta and kappa receptors binding.
There were multiple cases of the effects of morphine being reversed with CRH effects on the
HPA axis level, however the most pronounced changes were observed in the hypothalamus.
Interestingly, CRH reversed the effect of the morphine on the proenkephalin mRNA
expression in all tested tissues. These results indicated an important role of CRH in the
endogenous opioid peptides synthesis and opioid receptors binding.
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Endogenous opioid peptides and their receptors
play important roles in the regulation of many
physiological processes via nervous, endocrine
and immune systems interactions. Opioid pep-
tides, belonging to families of enkephalins, dynor-
phins and endorphins are synthesized as large
peptides (precursors) namely preproenkephalin
(PENK), preprodynorphin (PDYN) and proopio-
melanocortin (POMC), respectively.
Among opioid peptides, enkephalins have the
widest tissue distribution. They are released as na-
tive small molecules from multiple central ner-
vous system structures and peripheral organs such
as adrenals, gastrointestinal system, pancreas and
cardiovascular systems (PIERZCHALA & VAN LOON
1990). Met-enkephalin exists in the blood and tis-
sues in two forms –1. native with five amino acid
residues fragments and a very short half-life and 2.
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cryptic form in/or associated with large proteins
and processed by proteases to active Met-enkephalin
and Leu-enkephalin (PIERZCHALA & VAN LOON
1990). Under in vitro conditions, native Met-
enkephalin might be released from cryptic (bound)
precursor by enzymatic hydrolysis with trypsin
and carboxypeptidase B.
Endogenous opioids act through specific recep-
tors localized in both the brain and peripheral tis-
sues. Classical pharmacological studies identified
three classes of opioid receptors; mu (ì), delta (ä)
and kappa (ê) which have been cloned. These clas-
sical opioid receptors belong to the family of the
guanine regulatory binding (G) protein coupled re-
ceptor and are acting through the second messen-
ger systems mainly by inhibition of Gi/Go proteins
(BODNAR 2016). Pharmacological and molecular
studies suggested that there is more than one type
of mu opioid receptor. However, as only a single
mu receptor gene has been reported, so the recep-
tor may undergo extensive alternative splicing to
generate a group of variants (PASTERNAK & PAN
2011).
Endogenous opioid peptides have been broadly
studied as important factors modulating activity of
hypothalamic-pituitary-adrenal axis (HPA) (DROLET
et al. 2001; RUSSELL et al. 2008). Opioid-containing
neurons have been shown to innervate the median
eminence and paraventricular nucleus of the hypo-
thalamus, thereby regulating inputs to ACTH-
controlling neurons in the anterior pituitary (STEIN
& ZLLNER 2009; DI MARZO et al. 2007). Thus,
the hypothalamic-pituitary-adrenal axis represents
a modulatory target for the action of exogenous
and endogenous opioid ligands. Indeed, a growing
body of evidence suggests that opioids regulate
mechanisms activated during the stress response.
Conversely, the endogenous opioid system is acti-
vated by stressful situations, raising the possibility
that activation of the endogenous opioid system
may play a role in stress-mediated events. Al-
though stress is often linked to unpleasant events,
the stress response can be beneficial. For example,
exposure to mild stressors has been shown to acti-
vate the HPA axis, which is thought to play an im-
portant role in mediating cognitive adaptive
changes that promote survival. Previous studies
have shown that different stressors – emotional
(isolation) and physical (exercise) affect tissue and
plasma opioid concentrations and opioids recep-
tors activity in the hypothalamus, pituitary and ad-
renal (PIERZCHA£A-KOZIEC et al. 2006) indicating
a close relation between the opioid systems and
corticotrophin releasing hormone (CRH), adreno-
corticotrophic hormone (ACTH) and glucocorti-
coids. It was found that restraint stress increased
plasma concentrations of Met-enkephalin and cor-
ticosterone in rats (VAN LOON et al. 1990). Simi-
larly in sheep, the stress of insulin-induced
hypoglycemia increased plasma concentrations of
both cortisol and Met-enkephalin (OWENS et al.
1988). Enkephalins are present in the hypothala-
mus and interact with the CRH neurones (SMITH &
VALE 2006; VAN’T VEER et al. 2012; FUNK et al.
2014) and probably are secreted in order to modu-
late the activity of hypothalamic-pituitary-adrenal
axis (BRUCHAS et al. 2009; LEMERRER et al.
2009; LEMOS et al. 2012). In addition, the opioid
kappa receptor agonist, dynorphin, is co-localized
with corticotrophin-releasing hormone (CRH) in
hypothalamic neurons (CALOGERO et al. 1996).
Intravenous administration of either ì or ê selec-
tive opioid receptor agonists increases the circulat-
ing concentrations of adrenocorticotropin (ACTH)
in fetal lambs (TAYLOR et al. 1997). Based on
studies with the intracerebroventricular admini-
stration of Met-enkephalin and the consequent de-
crease in plasma concentration of ACTH, it can be
assumed that Met-enkephalin can depress ACTH
release acting at a central locus (WANG et al. 1988).
Morphine, an opium alkaloid acting through
µ opioid receptors, has been widely used as an an-
algesic for decades, however, there are side effects
such as respiratory depression, constipation and
nausea at the central and peripheral levels
(MATTHES et al. 1996; GENDRON et al. 2006).
There is contradictory information on the effects
of chronic morphine administration on hypotha-
lamic CRH. Long term treatment with morphine
was reported to decrease the CRH synthesis and
concentrations in the hypothalamus (LAORDEN et al.
2002). In contrast, chronic morphine administra-
tion was found to increase hypothalamic CRH
mRNA (MCNALLY & AKIL 2002; HOUSHYAR et al.
2004). Moreover, morphine administration to rats
increased plasma concentrations of ACTH (BUCK-
INGHAM 1982) and stimulated the release of CRH
(CALOGERO et al. 1996). In spite of fact that mor-
phine mainly acts through µ receptors it has been
demonstrated that acute or prolonged morphine
treatment upregulates delta and kappa receptors
(PIERZCHALA-KOZIEC et al. 2000; GENDRON et al.
2006).
Naloxone-induced morphine withdrawal is ac-
companied by stress-related parvocellular CRH
transcription (LIGHTMAN & YOUNG 1988; PASTER-
NAK & PAN 2011) again supporting cross-talk be-
tween opioid receptors and CRH (BRUNTON et al.
2005; CHONG et al. 2006; LIKAR et al. 2007;
CHARRON et al. 2008; RUSSELL et al. 2008).
Recent studies from our laboratory have shown
that CRH affects the mu, delta and kappa opioid re-
ceptors binding in each level of hypothalamic-
pituitary-adrenal cortical (HPA) axis and these ef-
fects can be influenced by naltrexone, an opioid re-
ceptorantagonist (PIERZCHA£A-KOZIEC etal. 2015).
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These results suggest that morphine and CRH
are involved into regulation of HPA axis in vary-
ing situations but whether their collective effects
represent a global mechanism acting to restraint
endogenous enkephalin peptides activity remains
to be elucidated.
Thus, the goals of the present study were two-
fold: 1. to determine whether single injection of
morphine affected the synthesis, secretion, con-
centration of native and cryptic Met-enkephalin
and mu, delta and kappa opioid receptor agonist
binding in the hypothalamus, anterior pituitary and
adrenal cortex of lambs, and 2. to explore the ef-
fect(s) of CRH on the morphine-induced changes
in these processes.
Materials and Methods
The study employed 3 months old lambs of the
Polish Mountain Sheep breed. These were main-
tained in a controlled environment (photoperiod
14L: 14D with lights on from 7a.m to 7 p.m) and at
a room temperature 20°C. The lambs had free ac-
cess to food and water. The protocol was approved
by the First Local Ethical Committee on Animal
Testing in Kraków (64/OP/2005/I LKE).
Eighteen female lambs were assigned to 3 groups
(n=6): control (C), morphine (MOR) and morphine
plus corticotrophin releasing hormone (MOR+CRH).
Each lamb received one intravenous injection of
saline (0.9% of NaCl in the control group), mor-
phine (MOR) (1 mg/kg b. w.) or morphine and
CRH (1 µg/kg b.w. Sigma, St. Louis, MO, USA).
Blood samples were taken to the heparinized tubes
just before (0 time) and 10, 20, 30 and 60 minutes
after the injection. The samples were immediately
centrifuged and the plasma was stored at -80°C.
The site of injection was left jugular vein, the
blood was taken from the right jugular vein. Ani-
mals were decapitated after anaesthesia. Hypo-
thalami, anterior pituitary glands and adrenal
cortex were dissected out one hour after treatment
injections. Tissues were divided into four parts and
directed to: 1. in situ hybridization to estimate pro-
enkephalin gene expression, 2. estimation of native
and cryptic Met-enkephalin by radioimmunoassay,
3. opioid receptors binding and 4. in vitro secretion
of native Met-enkephalin.
Proenkephalin mRNA gene expression was esti-
mated by modified method described by
LIGHTMAN & YOUNG (1987). Briefly, the frozen
fragments of hypothalamus, anterior pituitary and
adrenal cortex were sliced (14ìm sections) using a
Leica cryostat microtome (-22°C). The sections
were thaw-mounted on gelatin-covered micro-
scopic slides, and stored for 3 days at -20°C before
the assay. Then, tissue sections were thawed and
fixed in 4% formaldehyde in phosphate buffered
saline (PBS; pH 7.4) for 10 min. Then, sections
were acylated for 10 min in triethanolamine/acetic
anhydride (0.25%). Sections were dehydrated by
immersion through graded ethanol (70%, 80%,
95%, 100%) and in air dried.
After pre-hybridization, a synthetic deoxyoligo-
nucleotide, complementary to the fragment of rat
proenkephalin (PENK), was labeled using 35S-dATP
(1200 Ci/nmol) to obtain a specific activity about
4×106 cpm/ìl. The probes were diluted in a hy-
bridization buffer (formamide, dextran sulfate,
Saline-Sodium Citrate buffer (SSC), Denhardt’s
solution, yeast tRNA, herring sperm DNA). Hy-
bridization occurred during 20 h in humidified
chamber at 37°C. Then, the sections were washed
once in SSC for 10 min, then four times for 15 min,
each in SSC/ 50% formamide at 40°C, rinsed in
SSC and distilled water at room temperature and
air-dried. The sections were exposed to Kodak film
for four weeks (-80°C). The photo-stimulated lu-
minescence (PSL) density of the irradiated plates
was measured with BAS-1000 readout system.
The PSL/mm2 at the resultant film images was de-
termined using computer image analysis system.
Native and cryptic Met-enkephalin concentrations
Native and cryptic Met-enkephalin concentra-
tions in the tissues and plasma were estimated by
the radioimmunoassay method of PIERZCHA£A &
VAN LOON (1990). Briefly, fragments of tissues
were homogenized in phosphate buffer, pH 6.5,
centrifuged (4000×g, 4°C, 20 min) and super-
natants were stored at -80°C until further process-
ing. Enkephalin containing peptides (cryptic
enkephalin) were hydrolyzed with trypsin (1
mg/ml, 37°C, for 30 min) followed by car-
boxypeptidase B (5 mg/ml) plus trypsin inhibitor
(2.5 mg/ml) for 15 minutes.
Native and cryptic enkephalins were purified on
PorapakQ (Waters,100-120 mesh) in 2 ml of abso-
lute ethanol, lyophilized and assayed after recon-
stitution in 100 ìl of 0.06 M phosphate buffer (pH
6.5, 0.2% bovine serum albumin, 0.002% sodium
azide). The assay entailed the addition of 50 ìl an-
tiserum (rabbit, 1:10,000) and 50 ìl of 125I-Met-
enkephalin (~1500 cpm) and incubation at 4°C for
24 h. Bound and free opioid was separated after 24 h
by the addition of 50 ìl of rabbit ã-globulin (1%),
incubation for 30 min at 4°C, addition of 250 ìl of
25% polyethylene glycol (PEG 8000), incubation
for 30 min of incubation samples and finally cen-
trifugation (2000×g, 4°C, 20 min). The super-
natants were discarded and the pellets were
counted in a ã-counter (Wizard).
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Receptor binding assays
Receptors binding assays were performed
according to procedures reported by BELCHEVA et al.
(1994) and HYTREK et al. (1996) with some modifi-
cation (PIERZCHA£A-KOZIEC et al. 2015). Briefly,
the dissected tissues were homogenized in ice-
cold buffer 50 mM Tris-HCl, pH 7.4 and the ho-
mogenate was centrifuged at 20,000 xg for 15 min.
Cells membrane preparations (1 ml, 1 mg of pro-
tein) were incubated at 30ºC for 30 min with tri-
tiated agonists for each type of opioid receptors:
for mu receptors – 26.0 nM 3H-DAGO [D-Ala2,
MePhe4, Gly(ol)5]enkephalin, for delta receptor –
6.80nM 3H-DPDPE [[D-Ala2-,N-Me-Phe4,Gly-
ol] and for kappa receptor – 59.18 nM of 3H-EKC
([ethylketocyclazocine]). Radioligands were pur-
chased from Amersham International (3H-DAGO,
3H-DPDPE) and from New England Nuclear
(3H-EKC). Nonspecific binding was estimated with
10 µM of unlabeled ligands: Met-enkephalin for delta,
Leu- enkephalin-Arg for kappa and morphine for
mu receptors (Sigma, St. Louis, MO, USA). Free
ligand was separated from membrane bound
radioligand by filtration under reduced pressure
through GF/B Whatman glass filters. Protein con-
centrations were determined by the bicinchoninic
acid (BCA) method (OLSON & MARKWELL 2007).
In vitro Met-enkephalin secretion
Met-enkephalin secretion from fragments of tis-
sues was estimated according to the method of
KOWALSKI & GIRAUD (1993) with some modifi-
cations. Briefly, fragments of tissues (20-30 mg)
sliced by microtome were placed into 24-well plates
with 1 ml of Krebs-Ringer bicarbonate buffer (me-
dium). After a 20 min preincubation period, tissues
were incubated at 37°C for five successive 20 min
periods in 500l medium according to the sequence:
1. basal medium; 2. stimulating medium with 100 nM
of naltrexone; 3. basal medium; 4. basal medium;
5. stimulating medium with 56 mM KCl. Stimula-
tion with KCl served to validate survival of the tis-
sue through the experiment. The concentration of
Met-enkephalin in the basal media were not sig-
nificantly different so the results were pooled and
presented as Met-enkephalin release under basal
conditions.
Statistical analysis
Results are presented as means ± SEM. The
analysis was performed using the O Dell Statistica,
ver.13, (1984-2016 Dell Inc.). Repeated measures
ANOVA or paired t-test followed by Fisher test
were used to determine the effects of morphine and
CRH on the synthesis, secretion, plasma levels of
Met-enkephalin as well as mu, delta and kappa re-
ceptor binding in the HPA axis.
Results
Proenkephalin
There were some differences (P<0.001) in pro-
enkephalin (PENK) expression between each of the
three tissues: hypothalamic (464 ± 44 PSL/mm2),
anterior pituitary (761 ± 66 PSL/mm2) and adrenal
cortical tissues (663 ± 49 PSL/mm2). Figure 1
summarizes the effects of morphine or morphine
in combination with CRH on PENK mRNA con-
centrations in the hypothalamus, anterior pituitary
gland and adrenal cortex of sheep.
There was no effect of morphine on hypotha-
lamic PENK mRNA (Fig. 1). In contrast, an injec-
tion of morphine was followed by decreased
(P<0.001) PENK mRNA expression by 47% for
the anterior pituitary and by 55% in the adrenal
cortex (Fig. 1). Administration of morphine to-
gether with CRH influenced PENK expression.
PENK mRNA was increased (P<0.001) in the hy-
pothalamus, anterior pituitary gland and adrenal
cortex in lambs receiving CRH and morphine
compared to either control lambs or animals re-
ceiving morphine alone (Fig. 1).
Met-enkephalins concentrations
Native Met-enkephalin
There were much higher concentrations
(P<0.001) of native Met-enkephalin in the anterior
pituitary gland (138.3±8.92 pmol/g wt.) than ei-
ther hypothalamus (29.1±1.9 pmol/g w.t.) or adre-
nal cortex (33.5 ± 1.9 pmol/g wt.). The effects of
morphine or morphine in combination with CRH
on concentrations of native Met-enkephalin in the
Fig. 1. Effects of morphine and CRH on proenkephalin
mRNA expression in the hypothalamus, anterior pituitary
and adrenal cortex. Data is shown as mean in PSL/mm2 ± SEM
(n= 6 animals). Different superscript letter and asterisk (a,*)
indicate difference <0.05 compare to control and morphine
treated group, respectively. Treatments – C-control (injection of
saline), MOR-morphine injection, MOR+CRH – morphine
and CRH injections.
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hypothalamus, anterior pituitary gland and adrenal
cortex of lambs are shown in Fig. 2.
Injection of morphine alone or in combination
with CRH was not accompanied by changes in the
concentrations of native Met-enkephalin in the hy-
pothalamus (Fig. 2). Morphine administration was
accompanied by a 23% decline (P<0.05) in the
concentration of native Met-enkephalin in the an-
terior pituitary gland (Fig. 2). Moreover, injection
of both morphine and CRH was followed by
a larger (80%) decrease (P<0.001) in the concen-
tration of native Met-enkephalin in the anterior pi-
tuitary gland (Fig. 2). Morphine administration
also depressed (P<0.01) the concentration of na-
tive Met-enkephalin in the adrenal cortex by 27%
from 33.5 ± 1.9 to 24.3 ± 1.6 pmol/g wt. (Fig. 2).
Native Met-enkephalin concentrations after treat-
ment with morphine and CRH were intermediate
of the concentrations seen in control and morphine
but did not differ significantly from either (Fig. 2).
Cryptic Met-enkephalin
There were much higher concentrations (P<0.001)
of cryptic Met-enkephalin in the anterior pituitary
gland (216.9 ± 19.7 pmol/g wt.) than the hypo-
thalamus (43.1 ± 2.7 pmol/g wt.) with adrenal cor-
tex intermediate (160.9 ± 18.3 pmol/g wt.). Figure 3
summarizes the effects of morphine or morphine
together with CRH on the concentrations of cryp-
tic Met-enkephalin in the hypothalamus, anterior
pituitary gland and adrenal cortex of lambs.
Acute administration of morphine was accom-
panied by increased (P<0.01) concentrations of
cryptic Met-enkephalin in the hypothalamus and
anterior pituitary by, respectively, 35% and 33%
(Fig. 3). In contrast, the concentration of cryptic
Met-enkephalin in the adrenal cortex was reduced
(P<0.001) by 78% in lambs receiving injections of
morphine (Fig. 3). Administration of CRH in com-
bination with morphine reversed the effect of mor-
phine on hypothalamic concentrations of cryptic
Met-enkephalin (Fig. 3). Anterior pituitary con-
centrations of cryptic Met-enkephalin did not dif-
fer between lambs receiving morphine alone or
morphine together with CRH (Fig. 3). Adrenal
cortical concentrations of cryptic Met-enkephalin
were reduced in lambs receiving morphine plus
CRH with the decrease less (P<0.05) compared to
morphine injected group (Fig. 3).
Opioid receptors binding
Figure 4, 5 and 6 summarizes the effects of mor-
phine or morphine plus CRH on the hypothalamus,
anterior pituitary gland and adrenal cortex exam-
ining, respectively, mu (ì) opioid receptors
(MOR), delta () opioid receptors (DOR) and
kappa (ê) opioid receptors (KOR).
Mu (ì) opioid receptor binding (Fig. 4)
There was markedly greater (P<0.001) MOR as
indicated by binding (of 3H-DAGO) in adrenal
cortex (9.30 ± 0.82 fmol/mg protein) than hypo-
thalamus (5.16 ± 0.28 fmol/mg protein) and, in
turn, than the anterior pituitary gland (2.70 ± 0.24
fmol/mg protein). Neither hypothalamic nor adre-
nal cortical MOR were influenced by morphine
treatment (Fig. 4). Anterior pituitary MOR
(3H-DAGO binding) was decreased (P<0.001) by
63% in lambs receiving morphine administration
compared to control lambs (Fig. 4). Hypothalamic
ì opioid receptor concentrations were increased
Fig. 3. The effects of morphine and CRH on the cryptic
Met-enkephalin concentration in the hypothalamus,
anterior pituitary and adrenal cortex. Data is shown as mean
in pmol/g ± SEM (n= 6 animals). Different superscript
letter and asterisk (a,*) indicate difference <0.05 compare
to control and morphine treated group, respectively. Treatments
– C-control (injection of saline), MOR-morphine injection,
MOR+CRH – morphine and CRH injections.
Fig. 2. Effects of morphine and CRH on the native Met-enke-
phalin concentration in the hypothalamus, anterior pituitary
and adrenal cortex. Data is shown as mean in pmol/g ± SEM
(n= 6 animals). Different superscript letter and asterisk (a,*)
indicate difference <0.05 compare to control and morphine
treated group, respectively. Treatments – C-control (injection
of saline), MOR-morphine injection, MOR+CRH – morphine
and CRH injections.
CRH and Morphine Affect Met-enkephalin in HPA Axis 203
(P<0.001) by 96% in lambs receiving morphine to-
gether with CRH (Fig. 4). In contrast, anterior pi-
tuitary concentrations of MOR were lower in
lambs receiving morphine and CRH than either
morphine alone (89%) or than in control lambs
(98%) (Fig. 4). Administration of morphine to-
gether with CRH depressed (P<0.001) the ì opioid
agonist binding in adrenal cortex tissue by 46%
compared to tissue from control sheep.
Delta () receptor binding (Fig. 5)
There were similar DOR concentrations, as indi-
cated by binding of 3H-DPDPE, in adrenal corti-
cal, hypothalamic and anterior pituitary tissue –
39.12±4.11, 53.01±4.78 and 44.40±3.87 fmol/mg
protein, respectively. Lambs receiving a single in-
jection of morphine exhibited decreased
Fig. 4. Mu receptor receptors in the hypothalamus, anterior
pituitary and adrenal cortex as estimated by 3H-DAGO binding
to cell membrane preparations from lamb hypothalamus,
anterior pituitary and adrenal cortex. Data is shown as mean
in fmol/mg protein ± SEM (n= 6 animals). Different superscript
letter and asterisk (a,*) indicate difference <0.05 compare to
control and morphine treated group, respectively. Treatments
– C-control (injection of saline), MOR-morphine injection,
MOR+CRH – morphine and CRH injections.
Fig. 5. Delta opioid receptors in the hypothalamus, anterior
pituitary and adrenal cortex as estimated by 3H-DPDPE binding
to cell membrane preparations from lamb hypothalamus,
anterior pituitary and adrenal cortex. Data is shown as mean
in fmol/mg protein ± SEM (n= 6 animals). Different superscript
letter and asterisk (a,*) indicate difference <0.05 compare
to control and morphine treated group, respectively.
Treatments – C-control (injection of saline), MOR-morphine
injection, MOR+CRH – morphine and CRH injections.
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(P<0.001) DOR binding in the hypothalamus by
87%, anterior pituitary by 86% and adrenal cortex
by 59% (Fig. 5). CRH given together with mor-
phine caused small but statistically significant in-
creases in DOR binding in the hypothalamus and
anterior pituitary. In contrast, CRH potentiated the
inhibitory effect of morphine on the delta receptor
binding in the adrenal cortex.
Kappa (ê) receptor binding (Fig. 6)
There were marked tissue differences (P<0.001)
in kappa receptor binding as indicated by 3H-EKC
binding. Kappa receptor binding ranged from low-
est in the hypothalamus (19.2 ± 1.44 fmol/mg pro-
tein), intermediate in the anterior pituitary gland
(79.0 ± 6.39 fmol/mg protein) and highest in the
adrenal cortex (355.1 ± 37.2 fmol/mg protein in of
control lambs). There was no effect of morphine
alone or in combination with CRH on the KOR
agonist binding in the hypothalamus (Fig. 6). In
contrast, ê receptor agonist binding was increased
(P<0.001) in both anterior pituitary and adrenal
cortical tissue from lambs treated with morphine
(Fig. 6); the increases being, respectively, 53 and
122%. Administration of CRH with morphine fur-
ther increased (P<0.001) ê receptor agonist bind-
ing in anterior pituitary tissue. However, injection
of CRH with morphine attenuated (P<0.01) KOR
binding in the adrenal cortex.
Plasma concentrations of native Met-enkephalin
Plasma concentrations of native Met-enkephalin
levels were unchanged in control lambs during the
60 min course of the experiment (Fig. 7). In con-
trast, injection of morphine was followed rapidly
by decreased (P<0.01) plasma concentrations of
native Met-enkephalin (Fig. 7) being decreased by
63% after 10 min (P<0.01) and by 79% to a nadir
after 20 min (P<0.01) (Fig. 7). Plasma concentra-
tions of native Met-enkephalin remained reduced
(P<0.01) at 30 min and after 60 min (Fig. 7). CRH
partially overcame the inhibitory effects of mor-
phine on plasma concentrations of native Met-
enkephalin (Fig. 7). There was a transitory 44%
decrease (P<0.01) in plasma concentrations of na-
tive Met-enkephalin 10 min after morphine plus
CRH challenge (Fig. 7). After 20 min plasma level
of native Met-enkephalin was not different from
the value observed in control animals. At 30 min-
utes Met-enkephalin level was significantly higher
compare to control and morphine treated animals
(Fig. 7). Administration of morphine plus CRH
was followed by what appeared to be a biphasic
change in the plasma concentrations of native
Met-enkephalin with an initial 10 min decrease
(P<0.01), recovery at 20 min, overshoot at 30 min
(P<0.05) and a second decrease (P<0.05).
Met-enkephalin secretion in vitro from the hypo-
thalamus, anterior pituitary gland and adrenal cortex
Figure 8 summarizes in vitro secretion of Met-
enkephalin from the hypothalamus, anterior pitui-
tary gland and adrenal cortex of control lambs and
those treated with morphine or morphine and
CRH. In vitro secretion of Met-enkephalin was de-
Fig. 6. Kappa opioid receptors in the hypothalamus, anterior
pituitary and adrenal cortex as estimated by 3H-EKC binding
to cell membrane preparations from lamb hypothalamus,
anterior pituitary and adrenal cortex. Data is shown as mean
in fmol/mg protein ± SEM (n= 6 animals). Different superscript
letter and asterisk (a,*) indicate difference <0.05 compare to
control and morphine treated group, respectively. Treatments
– C-control (injection of saline), MOR-morphine injection,
MOR+CRH – morphine and CRH injections.
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termined in the presence or absence of the opioid
antagonist, naltrexone (Fig. 8).
Hypothalamus
Basal release of Met-enkephalin from the hypo-
thalamus in vitro was elevated in lambs receiving
morphine; increasing from 8.2 ± 0.78 pmol/g/20
min in controls to 17.9 ± 2.1 pmol/g/20 min with
morphine treatment (P<0.001) (Fig. 8). In con-
trast, Met-enkephalin secretion was reduced by
63% (P<0.01) in lambs receiving morphine and
CRH (Fig. 8). In the presence of naltrexone, there
was markedly increased release of Met-enkephalin
from hypothalamus of control animals by 187%
(P<0.01) (Fig. 8). However, there was reduced re-
lease of Met-enkephalin (by 72%, P<0.001) from
tissue from lambs injected with morphine (Fig. 8).
In contrast, there was increased secretion (by 250%,
P<0.001) of Met-enkephalin from the hypothala-
mus in the presence of naltrexone in tissue from
lambs injected with morphine and CRH (Fig. 8).
Fig. 7. The effects of morphine and CRH on the plasma concentrations of native Met-enkephalin in lambs. Data is shown as
mean in pmol/ml ± SEM (n= 6 animals). Different superscript letter and asterisk (a,*) indicate difference <0.05 compare to
control and morphine treated group, respectively. Treatments – C-control (injection of saline), MOR-morphine injection,
MOR+CRH – morphine and CRH injections.
Fig. 8. Effects of in vivo treatment (morphine or morphine + CRH) on in vitro secretion of Met-enkephalin. Release of native
Met-enkephalin was determined in vitro in the presence or absence of the opioid receptor antagonist, naltrexone from lamb
hypothalamus, anterior pituitary and adrenal cortex. Data is shown as mean in pmol/g/20 min ± SEM (n= 6 animals).
Naltrexone was at 100 nM. a, b – different superscript letters indicate difference between in vivo treatments P <0.05 x, y, z
different superscript letters indicate difference between in vitro treatment with naltrexone P <0.05. Treatments – C-control
(injection of saline), MOR-morphine injection, MOR+CRH – morphine and CRH injections.
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Anterior pituitary gland
Basal in vitro secretion of Met-enkephalin from
sheep anterior pituitary tissue was 5.9 fold greater
than from the hypothalamus (Fig. 8). Basal in vitro
secretion of Met-enkephalin was lower (P<0.001)
in lambs treated with morphine by 74% and with
morphine together with CRH (Fig. 8). The effect
of morphine was attenuated somewhat (P<0.05) in
the presence of CRH with secretion depressed
(P<0.001) by 62% in tissue from lambs receiving
morphine + CRH compared to control lambs (Fig. 8).
In the presence of naltrexone, Met-enkephalin
release in vitro was decreased (P<0.001) by 73%
with pituitary tissue from control lambs [from 48.3
± 3.4 to 12.9 ± 1.6 pmol/g/20 min] but increased
(P<0.001) by 2.95 fold from tissue of morphine in-
jected animals (from 12.5 ± 1.3 to 36.9 ± 4.5
pmol/g/20 min) (Fig. 8). Naltrexone did not affect
Met-enkephalin release in vitro (P>0.05) from an-
terior pituitary tissue from lambs treated with mor-
phine and CRH.
Adrenal cortex
Met-enkephalin release in vitro from the adrenal
cortex tissue is markedly lower than from hypotha-
lamic and anterior pituitary tissue. In vivo injection
of morphine increased secretion of Met-enkephalin
(P<0.05) by 22%. In the presence of naltrexone,
Met-enkephalin release was increased (P<0.001)
in adrenal cortical tissue from control lambs
(by 121%), from morphine treated animals (by 74%)
and from morphine with CRH injected lambs
(by 77%).
Discussion
There were novel and marked effects in vivo treat-
ment with morphine or morphine combined with CRH
on enkephalin related parameters and on opioid re-
ceptors (see Figs 1-8). The direct and magnitude of
effects results are summarized in Table 1.
The effects of morphine and morphine with CRH
on proenkephalin mRNA expression
Acute morphine injection did not change proen-
kephalin mRNA expression in hypothalamus but
significantly decreased it in anterior pituitary and
adrenal cortex (Fig. 1). It has been previously re-
ported that morphine administration can acutely
change opioid peptide gene transcription in rat
brain (BASHEER & TEMPEL 1993) and in specific
brain regions (YuKHANANOV & HANDA 1997).
Treatment with CRH completely reversed the ef-
fect of morphine and increased the proenkephalin
mRNA expression in all HPA axis levels.
There is evidence for cross-talk between CRH
and the opioid systems. IREDALE et al. (2000)
found extrahypothalamic CRH to be implicated in
anxiety and aversion associated with opiate with-
drawal. Type 1 CRH receptor (CRH-R1) antago-
nists attenuated behavioral signs of opiate
withdrawal as well as footshock stress-induced re-
instatement of heroin seeking and morphine-
conditioned place preference (WANG et al. 2006).
CRH plays a role in the elevation of withdrawal-
induced noradrenergic transmission (FUNADA et al.
1994). Moreover, chronic morphine selectively
sensitizes locus coeruleus norepinephrine neurons
to CRH (XU et al. 2004). These mechanisms con-
tribute to the facilitated neuroendocrine stress re-
sponse seen in morphine dependent rats after
withdrawal (HOUSHYAR et al. 2004).
The concentrations of cryptic and native Met-enke-
phalin in the hypothalamic-pituitary-adrenal axis
Data in the literature regarding opiate-induced
regulation of the brain enkephalin system are con-
troversial. Thus, increases or decreases in en-
kephalin immunoreactivity were reported to occur
in brain tissues after chronic treatment with mor-
phine, whereas in other studies, no change was ob-
served (VAN BOCKSTAELE et al. 2000). These
differences are probably due to the various experi-
mental protocols used in chronic morphine treat-
ment, the fragments of brain, different methods for
enkephalin estimation, autoradiography or in situ
hybridization and small opioid peptide extraction
from tissues (NIETO et al. 2002). In the present ex-
periments acute morphine caused increase of cryp-
tic enkephalin in the hypothalamus without any
serious changes in the native form of opioid. In
spite of lower synthesis of proenkephalin as an ef-
fect of decreased gene expression after acute mor-
phine, the concentration of cryptic Met-enkephalin
in the anterior pituitary was increased. This higher
level of cryptic enkephalin probably was an effect
of lower activity of enzymes responsible for proc-
essing large precursor to native form what resulted
in significantly lower concentration of native
Met-enkephalin. Met-enkephalins, cryptic and na-
tive, were decreased after morphine injection in
the adrenal cortex, probably due to inhibition of
synthesis and enzymatic hydrolysis. Corticotro-
phin releasing hormone potentiated stimulating ef-
fect of morphine on the cryptic Met-enkephalin
concentration and inhibiting effect of opiate on the
native opioid in the anterior pituitary. CRH re-
versed completely (hypothalamus) and partially
(adrenal cortex) morphine effects. It is interesting
that administration of CRH with morphine did not
influence the concentrations of either native or cryp-
tic Met-enkephalin in the hypothalamus despite
the elevated PENK mRNA expression (Table 1,
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Figs 1-3). It seems probable that mRNA expres-
sion did not mirror the proteins concentrations par-
ticularly these characterized by short half- life.
Opioid receptors binding
Mu receptor binding in the anterior pituitary
gland was decreased in lambs receiving injections
of morphine (Fig. 4). However, there were no ef-
fects in the hypothalamus and adrenal cortex sug-
gesting an absence of down regulation and
probably lack of receptor internalization in the hy-
pothalamus and adrenal. Treatment with CRH
along with morphine was accompanied with marked
shifts in mu receptors with the suppressive effects
of morphine on the anterior pituitary gland aug-
mented, mu receptors binding in the hypothalamus
increased and mu receptors binding in the hypo-
thalamus decreased (Fig. 4). Administration of in-
jection alone CRH was observed to increase the
mu receptor binding in the hypothalamus
(PIERZCHA£A-KOZIEC et al. 2015). It is possible
that 3H-DAGO could not bind in vitro to receptors
that were persistently occupied by morphine or
other opioid agonists. KISSIN et al. (1991) postu-
lated that the absence of correlation between anal-
Table 1
Summary of the acute effects of morphine or combined treatment with morphine and CRH
on Met-enkephalin and opioid receptors in the hypothalamus, anterior pituitary gland and
adrenal cortex of lambs (based on data in Figs 1-8). The effects of treatments were com-
pared to control column
Parameter Control Morphine Morphine + CRH
Hypothalamus
Pro-enkephalin expression
  
Met-enkephalin release in vitro
  
Effect of naltrexone in vitro
  
Cryptic Met-enkephalin concentration
  
Native Met-enkephalin concentration
  
Delta opioid receptor binding
  
Kappa opioid receptor binding
  
Mu receptor receptor binding
  
Anterior pituitary gland
Pro-enkephalin expression
  
Met-enkephalin release in vitro
  
Effect of naltrexone in vitro
  
Cryptic Met-enkephalin concentration
  
Native Met-enkephalin concentration
  
Delta opioid receptor binding
  
Kappa opioid receptor binding
  
Mu receptor receptor binding
  
Adrenal cortex
Pro-enkephalin expression
  
Met-enkephalin release in vitro
  
Effect of naltrexone in vitro
  
Cryptic Met-enkephalin concentration
  
Native Met-enkephalin concentration
  
Delta opioid receptor binding
  
Kappa opioid receptor binding
  
Mu receptor receptor binding
  
Plasma
Concentration of Met-enkephalin
  
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gesia and morphine brain concentration both with
the constant-rate morphine infusion and after a sin-
gle injection; suggesting the development of acute
tolerance. Data should be interpreted with caution
about varied doses of morphine, animal species
and methodology of experiments.
Injection of morphine greatly reduced in vitro
binding of 3H-DPDPE to delta receptors in hypo-
thalamic, anterior pituitary and adrenal cortical tis-
sues (Fig. 5). In contrast, prolonged or acute mor-
phine treatment has been reported to upregulate
delta and kappa receptors in the HPA axis
(PIERZCHALA-KOZIEC et al. 1990; 2000; GENDRON
et al. 2006). Co-treatment of CRH with morphine
partially reversed the effects of morphine on the
hypothalamus and adrenal cortex but increased the
inhibiting effect of morphine on the 3H-DPDPE
binding in the adrenal cortex. Similarly, admini-
stration of injection CRH reduced delta receptor
binding in each level of the HPA axis (PIERZCHA£A
-KOZIEC et al. 2015). These data agree with the report
of agonist induced activation of the delta opioid re-
ceptor leads to receptor desensitization and finally
to internalization (PRADHAN et al. 2009; 2012).
The level of kappa receptor binding varied mark-
edly from the lowest in the hypothalamus, inter-
mediate in the anterior pituitary gland and highest
in adrenal cortex (Fig. 6). The presence of kappa
opioid receptor in the lamb hypothalamus is con-
sistent with the role for kappa receptors in
modulating the release of luteinizing hormone
(GOODMAN et al. 2004; LOPEZ et al. 2016), thyro-
trophin releasing hormone and growth hormone
releasing hormone (DEPAOLI et al. 1994; FUNK et
al. 2014) and the presence of ê-opioid receptors
located in GnRH neurones (WEEMS et al. 2016).
Dynorphin and alfa-neo-endorphin are the main
agonists for kappa receptors. Dynorphin has been
found to regulate neuronal excitability broadly in
brain and can affect learning, cognition, seizures,
nociception, and endocrine function. Recently, ac-
tivation of the dynorphin/kappa receptor system
has also been shown to be necessary and sufficient
for stress-induced behavioral responses in animal
models of anxiety, depression, and drug seeking
behaviors (VANDERAH 2010).
In the present study, acute treatment with mor-
phine alone or in combination with CRH did not
influence kappa receptor binding in the hypothala-
mus of lambs (Fig. 6). This may be due to antago-
nistic properties of mu receptor agonists at the
central level. PFEIFFER et al. (1986) reported that
kappa receptor agonists are responsible for induc-
tion dysphoric and psychomimetic effects in con-
trast to mu receptors agonists. In contrast, there
were increases following morphine injection in
3H-EKC binding to kappa receptor in the anterior
pituitary gland and adrenal cortex (Fig. 6). The
effect was potentiated by CRH on the anterior pi-
tuitary gland but attenuated by CRH with adrenal
cortical tissue (Fig. 6). These tissue differences
may reflect different class of kappa receptors and
this could be investigated using novel and new
kappa agonists that never enter the CNS (VAN-
DERAH 2010). The role of CRH-induced activation
of the kappa receptors and dynorphin opioid pep-
tides has been implicated as a mediator of adverse
responses to stress. Stress-induced release of
dynorphins has been reported to potentiate the “re-
ward” effects of drugs e.g. cocaine, ethanol and
nicotine (VAN’T VEER et al. 2012, 2013). Kappa
receptors activity has been linked to circulating
concentrations of corticosterone levels as there is a
faster rate of increase of corticosterone following
stress in mice lacking dynorphin (BILKEI-GORZO
et al. 2008).
Plasma native Met-enkephalin concentrations
Plasma concentrations of Met-enkephalin were
markedly reduced following administration of
morphine with the nadir 20 minutes after injection
(Fig 7). Interestingly, to our best knowledge it is
first report about morphine decreasing plasma
concentrations of Met-enkephalin level. Plasma
concentrations of Met-enkephalin showed ten-
dency to increase by 60 min following morphine
challenge (Fig. 7). The magnitude of the decline in
plasma concentrations of Met-enkephalin (Fig. 7)
coupled with the short half-life of Met-enkephalin
suggests an even greater decrease in the release
and/or production of Met-enkephalin. The present
results with morphine administration are consis-
tent with the anterior pituitary and/or the adrenal
cortex being significant sources of circulating
Met-enkephalin.
Combined injection of morphine and CRH
evoked a biphasic effect on plasma concentrations
of Met-enkephalin with an initial decrease, recov-
ery and then increase up to 30 min. This is arguably
analogous to the response of rats to stressors with
an immediate increase of native Met-enkephalin
(around 1 min), then return to basal levels and sec-
ond peak of opioid after 30 minutes (PIERZCHALA
et al. 1987). The response to morphine was com-
pletely abolished in the presence of CRH at 20 and
30 minutes following challenge and attenuated
at 60 minutes (Fig. 7). It is suggested that CRH is
effectively acting as an antagonist. It is further
suggested that the loss of effectiveness of CRH in
depressing the effects of morphine on plasma con-
centrations of Met-enkephalin 60 minutes after
challenge was due to prolonged clearance of CRH
and appears to be responsible for the sustained re-
lease of ACTH that occurs after injection of this
hormone.
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In vitro Met-enkephalin release from HPA
Short-term in vitro incubations allowed direct
examination of Met-enkephalin secretion (Fig. 8).
There were marked tissue differences with hypo-
thalamic and adrenal cortical release of Met-
enkephalin (increase) in morphine treated lambs
and anterior pituitary decreased release of Met-
enkephalin in morphine treated lambs (Fig. 8).
Morphine treatment in vivo influenced the release
of Met-enkephalin in vitro; stimulatory for hypo-
thalamus and inhibitory for the anterior pituitary
gland. There is evidence that the effects of mor-
phine are direct as they are reversed in the presence
of the opioid receptors antagonist, naltrexone, in
the incubation media (Fig. 8). It is also likely that
basal release of Met-enkephalin from each tissue is
influenced by an endogenous opioid receptor an-
tagonist because there are shifts in the release of
Met-enkephalin in the presence of naltrexone. Ad-
ministration of CRH along with the morphine was
accompanied by reduced release of Met-enkephalin
from the hypothalamus compared to either control
or morphine treated lambs (Fig. 8). Moreover, in
vivo treatment with CRH along with morphine
overcame the effects of morphine on release of
Met-enkephalin fromanteriorpituitary tissue (Fig.8).
Basal Met-enkephalin in vitro release from the
adrenal cortex was lower than from hypothalamus
and anterior pituitary. Interestingly, morphine in-
jection increased the enkephalin basal release but
CRH again reversed this effect. There were con-
sistent in vitro stimulatory effects of naltrexone on
release of Met-enkephalin from adrenal cortical
tissue. These results provide clear evidences for a
physiological role for Met-enkephalin in the adre-
nal cortex. Met-enkephalin and other opioid recep-
tor agonists have been reported to increase
production of both aldosterone and corticosterone
by rat adrenocortical cells with the effects medi-
ated by, respectively, mu and both mu and kappa
receptors (KAPAS et al. 1995). Moreover, opioid
agonists were reported to increase cortisol produc-
tion by porcine adrenal cortical cells (KRAZINSKI
et al. 2011).
Summary
The anterior pituitary gland had consistently
higher concentrations of PENK mRNA, native and
cryptic Met-enkephalin and basal release of Met-
enkephalin in vitro than either the hypothalamus or
adrenal cortex. Acute morphine injection affected
synthesis, concentrations of both forms of Met-
enkephalin, agonists receptor binding as well as
opioid release in the hypothalamic-anterior
pituitary-adrenal cortex axis. However, it must be
pointed that the morphine effect on the hypotha-
lamic Met-enkephalin changes were much smaller
than in other tested tissues. This contention is sup-
ported by morphine decreasing the following: an-
terior pituitary gland PENK expression in both the
anterior pituitary gland and adrenal cortex (Fig. 1),
native Met-enkephalin in both the anterior pitui-
tary gland and adrenal cortex (Fig. 2) and cryptic
Met-enkephalin in the adrenal cortex (Fig. 3).
Moreover, in the case of the anterior pituitary
gland, tissue for morphine treated lambs exhibited
much reduced in vitro release of Met-enkephalin
(Fig. 8). Treatment with CRH either attenuated or
augmented effects of morphine (Table 1) depend-
ing on the tissue and enkephalin activity.
In conclusion, the present data demonstrated
acute effects of morphine on the synthesis, secre-
tion and concentrations of native and cryptic Met-
enkephalin. The present results provide further
support for the cross-talk between mu, delta and
kappa receptors and the HPA axis. Furthermore,
evidence is advanced supporting the ability of
CRH to attenuate some of the effects of morphine
and to augment other effects of morphine.
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